- Home
- / HTG Molecular
HTG Molecular
Total Funding
$69.7 M
Revenue
$6.4 M
FY, 2022
HTG Molecular Summary
Company Summary
- Overview
- HTG Molecular Diagnostics is a company that specializes in precision medicine. It offers HTG EdgeSeq, a profiling technology that provides transcriptome gene expression analysis; HTG EdgeSeq, an instrumentation to automate HTG EdgeSeq; and other solutions.
- Type
- Private
- Status
- Active
- Founded
- 1997
- HQ
- Tucson, AZ, US | view all locations
- Website
- http://www.htgmolecular.com
- Cybersecurity rating
Table of Contents
Key People
Byron T. Lawson, Senior Vice President and Chief Commercial Officer
Stephen A. Barat, Senior Vice President of Therapeutics
Ann F. Hanham, Chair of the Board
Operating MetricsView all
Patents (Foreign)
51
4.1%
FY, 2020
Patent Applications
6
68.4%
FY, 2020
Patent Families
12
7.7%
FY, 2020
LocationsView all
1 location detected
Tucson, AZ HQ
United States
3430 E Global Loop
HTG Molecular Financials
Summary Financials
- Revenue (Q1, 2023)
- $1.0M
- Gross profit (Q1, 2023)
- ($117.1K)
- Net income (Q1, 2023)
- ($5.1M)
- Cash (Q1, 2023)
- $3.0M
- EBIT (Q1, 2023)
- ($5.0M)